ストックスクリーナーアプリを入手
808.05
3.02%
23.69
アフターアワーズ：
808.05
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class ActionContact The Gross Law Firm - PR Newswire
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses - PR Newswire
(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - PR Newswire
Regeneron Says Drug Approval Irrelevant In Antitrust Case - Law360
Regeneron on track to build in Saratoga - The Daily Gazette
Regeneron Pharmaceuticals (REGN) Q2 2026 Preview: EPS Est. $10.26, Reports July 30 - AlphaStreet
REGN DEADLINE: Levi & Korsinsky Reminds Regeneron - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire Inc.
Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
$REGN Lawsuit Notice: BFA Law Reminds Regeneron Investors - GlobeNewswire
14,700 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Orbimed Advisors LLC - MarketBeat
3,883 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Lombard Odier Asset Management Switzerland SA - MarketBeat
Renaissance Technologies LLC Has $51.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Family Manage LLC - MarketBeat
Entropy Technologies LP Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN) - simplywall.st
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lombard Odier Asset Management Europe Ltd Sells 3,124 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Sei Investments Co. Buys 18,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Arrowstreet Capital Limited Partnership Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of September 14, 2026 Deadline - ACCESS Newswire
GC Wealth Management RIA LLC Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Lido Advisors LLC - MarketBeat
Epoch Investment Partners Inc. Has $184.45 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock trades steadily as recent Eylea growth and pipeline advances frame valuation - AD HOC NEWS
Cannell & Spears LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron: I’m Not Concerned About The Declining ROIC And Operating Margins (NASDAQ:REGN) - Seeking Alpha
Regeneron Q2 Earnings Preview: Not Expecting MiraclesAt Least In The Short Term (REGN) - Seeking Alpha
TrumpRx.gov Savings Top $700 Million as Praluent Added at 60% DiscountNews and Statistics - IndexBox
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - GlobeNewswire Inc.
The Scientist With 1,000 Patents Fueling a Drug Powerhouse - WSJ
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate FailureHBSS - PR Newswire
Regeneron stock trades near record levels as Eylea and Dupixent drive revenue growth - AD HOC NEWS
$REGN Fraud Notification: Regeneron Sued for Fraud Over - GlobeNewswire
Gibbs Wealth Management Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Bank of Nova Scotia - MarketBeat
Bessemer Group Inc. Sells 2,653 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Urged to Join Class Action Before September 14, 2026Contact Levi & Korsinsky - ACCESS Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. LawsuitREGN - Morningstar
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a - GlobeNewswire
Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report - Barchart.com
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 - New Castle News
Militia Capital Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
First Trust Advisors LP Buys 141,123 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN) Projected to Release Earnings on Thursday - MarketBeat
Andra AP fonden Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (REGN) Could Be 19% Undervalued After Recent Pipeline Focus - simplywall.st
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE - GlobeNewswire
INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - PR Newswire
ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks - TradingView
Westpac Banking Corp Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
REGN Court Alert: Regeneron Investors Seeking to Recover - GlobeNewswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Investors in Regeneron Pharmaceuticals, Inc. (REGN): Protect Your RightsContact Levi & Korsinsky Before September 14, 2026 - ACCESS Newswire
Regeneron stock trades steady as recent earnings and pipeline progress frame valuation - Ad-hoc-news.de
Securities Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (REGN)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law - marketscreener.com
Lobbying Update: $630,000 of REGENERON PHARMACEUTICALS INC lobbying was just disclosed - Quiver Quantitative
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785 - Moomoo
0.12%
大文字化:
|
ボリューム (24 時間):